Clinical bottom line
Immunotherapy is increasingly recognized as a valuable component in the treatment landscape of nasopharyngeal carcinoma (NPC), particularly in recurrent or metastatic settings. Immune checkpoint inhibitors targeting PD-1/PD-L1 pathways have demonstrated promising efficacy and manageable safety profiles. Emerging data also highlight the role of the tumor immune microenvironment and tertiary lymphoid structures as predictors of immunotherapy response. While immunotherapy is not yet standard frontline treatment, ongoing trials and translational research support its integration alongside chemotherapy and radiotherapy to improve outcomes in selected patients (Guo et al., 2026; Wong et al., 2021; Lv et al., 2023).
What the evidence shows
Guo et al. (2026) provide a comprehensive overview of current immunotherapeutic strategies in NPC, emphasizing the clinical benefits of PD-1 inhibitors in advanced disease. Their review notes objective response rates ranging from 20% to 30% in heavily pretreated populations, with durable responses observed in a subset of patients.
Wong et al. (2021) describe the evolving paradigm of NPC management, underscoring the immunogenic nature of Epstein-Barr virus (EBV)-associated tumors and the rationale for immunotherapy. They highlight that combining immunotherapy with chemotherapy or radiotherapy may enhance antitumor immunity.
Lv et al. (2023) analyze the tumor immune microenvironment after gemcitabine plus cisplatin chemotherapy, revealing increased infiltration of immune effector cells and upregulation of interferon-responsive genes. These changes may sensitize tumors to subsequent immunotherapy.
Liu et al. (2025) identify interferon-responsive high endothelial venules (HEVs) that promote tertiary lymphoid structure formation in NPC, correlating with improved immunotherapy response. This mechanistic insight supports biomarker-driven patient selection.
Kwong et al. (2019) review cancer immunotherapy approaches in NPC, including adoptive T-cell therapies targeting EBV antigens, which show preliminary efficacy but require further validation.
Caveats and uncertainty
Most immunotherapy data derive from phase II trials or retrospective analyses; large phase III randomized controlled trials are ongoing.
Response rates remain modest, and biomarkers predictive of benefit are not yet standardized for clinical use.
Optimal sequencing and combination regimens with chemotherapy and radiotherapy are not fully established.
Immune-related adverse events, while generally manageable, require vigilance and expertise.
The heterogeneity of NPC subtypes and geographic variations may affect generalizability.
How this may change practice
Clinicians should consider immunotherapy for patients with recurrent or metastatic NPC, especially after progression on standard chemotherapy.
Integration of immune checkpoint inhibitors into earlier treatment lines may become standard pending results from ongoing trials.
Assessment of tumor immune microenvironment features and biomarkers could guide patient selection and predict response.
Multimodal treatment strategies combining immunotherapy with chemotherapy or radiotherapy may improve outcomes.
Enhanced multidisciplinary collaboration and patient education on immunotherapy benefits and risks are essential.